Anti-cancer oncolytic virus combination therapies and elite responder selection platforms
US11433108B2 · kind B2 · utility
0Cited by
4References
9Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 28, 2017 |
| Grant date | Sep 6, 2022 |
| Priority date | — |
| Expiry date | Dec 12, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2710/24132
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Therapeutic methods for administering gut microbiota and oncolytic viruses to a subject are provided. The gut microbiota serve to pre-condition, the subject's immune system to antitumor responses and augments anticancer activity of the oncolytic vims. Combinations of the gut. microbiota and viruses and uses thereof for treating and preventing cancer are provided. The present disclosure also provides methods for building elite responder selection platforms through hierarchical clustering analysis of genomic profiles for human gut microbiome.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.